Trials: BMS And AbbVie's Elotuzumab, Amgen's Trebananib, Novartis' JAKAVI - EULAR: AbbVie's HUMI

New Stories

• If the minister is too embarrassed to respond, it might be the best of bad responses

  September 19, 2025 - - Latest News

• Mark Butler acknowledges his concerns over potential impact of US pharmaceutical pricing reforms

  September 19, 2025 - - Latest News

• CSL appoints new global head of search to accelerate innovation through strategic partnerships

  September 18, 2025 - - Latest News

• Pharmacy Guild of Australia acquires Member Benefits Australia

  September 18, 2025 - - Latest News

• Sanofi promotes a national dialogue on health literacy and trust

  September 18, 2025 - - Latest News

• Island Pharmaceuticals reports breakthrough survival data for galidesivir in Marburg and Ebola studies

  September 17, 2025 - - Australian Biotech

• Australian Dementia Network Registry wants access to 'turning point' therapies

  September 17, 2025 - - Latest News